{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:35:30Z","timestamp":1792532130356,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mechanisms of Ageing and Development"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1016\/j.mad.2004.08.023","type":"journal-article","created":{"date-parts":[[2004,10,24]],"date-time":"2004-10-24T03:07:07Z","timestamp":1098587227000},"page":"317-326","source":"Crossref","is-referenced-by-count":101,"title":["Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases"],"prefix":"10.1016","volume":"126","author":[{"given":"Moussa B.H.","family":"Youdim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mati","family":"Fridkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mad.2004.08.023_bib1","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1176\/jnp.13.3.374","article-title":"Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep","volume":"13","author":"Aarsland","year":"2001","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.mad.2004.08.023_bib2","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/(SICI)1097-4547(19991101)58:3<456::AID-JNR12>3.0.CO;2-S","article-title":"Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen\u2013glucose deprivation","volume":"58","author":"Abu-Raya","year":"1999","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.mad.2004.08.023_bib3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/00001756-200103260-00045","article-title":"Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment","volume":"26","author":"Arnaiz","year":"2001","journal-title":"Neuroreport"},{"key":"10.1016\/j.mad.2004.08.023_bib4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.neulet.2003.10.067","article-title":"Contrasting neuroprotective and neurotoxic actions of respective metabolites of antiparkinson drugs rasagiline and selegiline","volume":"355","author":"Bar Am","year":"2004","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.mad.2004.08.023_bib5","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1471-4159.2004.02425.x","article-title":"Regulation of amyloid precursor protein and protein kinase C functional machinery by the anti-Parkinson drug, rasagiline and its derivatives, in vivo","volume":"89","author":"Bar Am","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mad.2004.08.023_bib6","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.neuropharm.2003.09.005","article-title":"Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats","volume":"46","author":"Ben Shachar","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.mad.2004.08.023_bib7","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1111\/j.1471-4159.1991.tb11444.x","article-title":"The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons","volume":"56","author":"Ben Shachar","year":"1991","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mad.2004.08.023_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF00176837","article-title":"Is the forced swimming test a suitable model for revealing antidepressant activity?","volume":"94","author":"Borsini","year":"1988","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.mad.2004.08.023_bib9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0024-3205(00)00643-3","article-title":"Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat","volume":"67","author":"Carrillo","year":"2000","journal-title":"Life Sci."},{"key":"10.1016\/j.mad.2004.08.023_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-0173(98)00046-0","article-title":"An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration","volume":"29","author":"Cassarino","year":"1999","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.mad.2004.08.023_bib11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0161-813X(03)00114-1","article-title":"The FAD binding sites of human monoamine oxidases A and B","volume":"25","author":"Edmondson","year":"2004","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.mad.2004.08.023_bib12","first-page":"495","article-title":"Pharmacology of rasagiline (N-propargyl-1R-aminoindan)","volume":"80","author":"Finberg","year":"1999","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.mad.2004.08.023_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1476-5381.1981.tb16772.x","article-title":"Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B","volume":"73","author":"Finberg","year":"1981","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.mad.2004.08.023_bib14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1476-5381.1985.tb08891.x","article-title":"Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat","volume":"85","author":"Finberg","year":"1985","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.mad.2004.08.023_bib15","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00002512-200118120-00001","article-title":"Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?","volume":"18","author":"Giacobini","year":"2001","journal-title":"Drugs Aging"},{"key":"10.1016\/j.mad.2004.08.023_bib16","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","article-title":"A controlled clinical trial of rasagiline in early Parkinson's disease: the TEMPO Study","volume":"59","author":"Parkinson Study Group","year":"2002","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.mad.2004.08.023_bib17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archneur.61.4.561","article-title":"A controlled randomized, delayed-start study of rasagiline in early Parkinson's disease","volume":"61","author":"Parkinson Study Group","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.mad.2004.08.023_bib18","first-page":"1","article-title":"Effects of R-apomorphine and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss","volume":"76","author":"Grunblatt","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mad.2004.08.023_bib19","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1046\/j.1471-4159.1995.64031216.x","article-title":"Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type","volume":"64","author":"Gsell","year":"1995","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mad.2004.08.023_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0014-2999(85)90168-2","article-title":"Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B","volume":"116","author":"Heikkila","year":"1985","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.mad.2004.08.023_bib21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0014-2999(98)00929-7","article-title":"Neuroprotective effect of rasagiline, a selective MAO-B inhibitor, against closed head injury in the mouse","volume":"366","author":"Huang","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.mad.2004.08.023_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1592\/phco.20.1.1.34664","article-title":"Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease","volume":"20","author":"Jann","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.mad.2004.08.023_bib23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1476-5381.1981.tb16771.x","article-title":"Selective acetylenic \u2018suicide\u2019 and reversible inhibitors of monoamine oxidase types A and B","volume":"73","author":"Kalir","year":"1981","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.mad.2004.08.023_bib24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0047-6374(00)00144-5","article-title":"Mechanism underlying anti-apoptotic activity of a (\u2212)deprenyl-related propargylamine, rasagiline","volume":"116","author":"Maruyama","year":"2000","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.mad.2004.08.023_bib25","first-page":"171","article-title":"Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022","volume":"60","author":"Maruyama","year":"2000","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/j.mad.2004.08.023_bib26","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1749-6632.2001.tb03641.x","article-title":"Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022","volume":"939","author":"Maruyama","year":"2001","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.mad.2004.08.023_bib27","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1046\/j.1471-4159.2001.00448.x","article-title":"Transfection-enforced Bcl-2 over expression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol","volume":"78","author":"Maruyama","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mad.2004.08.023_bib28","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0304-3940(03)00211-8","article-title":"Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor","volume":"341","author":"Maruyama","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.mad.2004.08.023_bib29","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","article-title":"Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB). Report of the consortium on DLB international workshop","volume":"47","author":"McKeith","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.mad.2004.08.023_bib30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1474-4422(03)00619-7","article-title":"International Psychogeriatric Association Expert Meeting on DLB. Dementia with Lewy bodies","volume":"3","author":"McKeith","year":"2004","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.mad.2004.08.023_bib31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1046\/j.1468-1331.2001.00224.x","article-title":"Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up","volume":"8","author":"Moretti","year":"2001","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.mad.2004.08.023_bib32","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1046\/j.1471-4159.1994.63062179.x","article-title":"Cortical cytochrome oxidase activity is reduced in Alzheimer's disease","volume":"63","author":"Mutisya","year":"1994","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mad.2004.08.023_bib33","first-page":"259","article-title":"N-methyl(R)salsolinol, a dopamine neurotoxin, in Parkinson's disease","volume":"80","author":"Naol","year":"1999","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.mad.2004.08.023_bib34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0165-0327(98)00070-6","article-title":"The prevalence of depression in Alzheimer's disease and vascular dementia in a population sample","volume":"52","author":"Newman","year":"1999","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.mad.2004.08.023_bib35","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/ana.410230616","article-title":"Possible neurotransmitter basis of behavioral changes in Alzheimer's disease","volume":"23","author":"Palmer","year":"1988","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.mad.2004.08.023_bib36","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ana.410260606","article-title":"Abnormalities of the electron transport chain in idiopathic Parkinson's disease","volume":"26","author":"Parker","year":"1989","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.mad.2004.08.023_bib37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0022-510X(90)90236-G","article-title":"Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly","volume":"95","author":"Perry","year":"1991","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.mad.2004.08.023_bib38","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0014-2999(79)90366-2","article-title":"Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity","volume":"57","author":"Porsolt","year":"1979","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.mad.2004.08.023_bib39","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1046\/j.1471-4159.2003.01801.x","article-title":"Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor","volume":"86","author":"Sagi","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mad.2004.08.023_bib40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0306-4522(94)90311-5","article-title":"Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative radioautography","volume":"62","author":"Saura","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.mad.2004.08.023_bib41","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ana.410350507","article-title":"Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease","volume":"35","author":"Simpson","year":"1994","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.mad.2004.08.023_bib42","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1749-6632.1999.tb08035.x","article-title":"The future of neuroprotection","volume":"890","author":"Slikker","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.mad.2004.08.023_bib43","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/978-3-7091-6499-0_29","article-title":"Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders","volume":"52","author":"Speiser","year":"1998","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/j.mad.2004.08.023_bib44","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1021\/jm020120c","article-title":"Novel dual inhibitors of AChE and MAO derived from hydroxyl aminoindan and phenethylamine as potential treatment for Alzheimer's disease","volume":"45","author":"Sterling","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mad.2004.08.023_bib45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/archneur.1996.00550020087019","article-title":"The occurrence of depression in Parkinson's disease. A community-based study","volume":"53","author":"Tandberg","year":"1996","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.mad.2004.08.023_bib46","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1124\/jpet.301.2.753","article-title":"Propargylamines induce anti-apoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells","volume":"301","author":"Tatton","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.mad.2004.08.023_bib47","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00702-002-0827-z","article-title":"Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B","volume":"110","author":"Tatton","year":"2003","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.mad.2004.08.023_bib48","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1096\/fj.04-1916fje","article-title":"Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members","volume":"18","author":"Weinreb","year":"2004","journal-title":"FASEB J."},{"issue":"Suppl.","key":"10.1016\/j.mad.2004.08.023_bib49","first-page":"157","article-title":"TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease","volume":"60","author":"Weinstock","year":"2000","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.mad.2004.08.023_bib50","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/1098-2299(200007\/08)50:3\/4<216::AID-DDR4>3.0.CO;2-Z","article-title":"Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities","volume":"50","author":"Weinstock","year":"2000","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.mad.2004.08.023_bib51","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1749-6632.2001.tb03622.x","article-title":"Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs","volume":"939","author":"Weinstock","year":"2001","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.mad.2004.08.023_bib52","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s00213-001-0978-x","article-title":"Effect of TV3326, a novel monoamine-oxidase-cholinesterase inhibitor, in rat models of anxiety and depression","volume":"160","author":"Weinstock","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.mad.2004.08.023_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/S0028-3908(02)00176-4","article-title":"Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A\u2013B inhibitor, TV-3326 in conscious rabbits","volume":"43","author":"Weinstock","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.mad.2004.08.023_bib54","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0278-5846(03)00053-8","article-title":"A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease","volume":"27","author":"Weinstock","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.mad.2004.08.023_bib55","series-title":"Mapping the Progress of Alzheimer's and Parkinson's Disease","article-title":"TV3326, a novel cholinesterase and MAO inhibitor for Alzheimer's disease with co-morbidity of Parkinson's disease and depression","author":"Weinstock","year":"2003"},{"key":"10.1016\/j.mad.2004.08.023_bib56","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1096\/fj.02-0198fje","article-title":"The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline","volume":"16","author":"Yogev-Falach","year":"2002","journal-title":"FASEB J."},{"key":"10.1016\/j.mad.2004.08.023_bib57","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1096\/fj.03-0078fje","article-title":"The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing","volume":"17","author":"Yogev-Falach","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.mad.2004.08.023_bib58","first-page":"555","article-title":"Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug, TV3326 [(n-propargyl-(3r)aminoindan-5-yl)-ethyl methyl carbamate]","volume":"21","author":"Youdim","year":"2001","journal-title":"Cell Mol. Biol."},{"key":"10.1016\/j.mad.2004.08.023_bib59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1749-6632.1999.tb07977.x","article-title":"The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators","volume":"890","author":"Youdim","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.mad.2004.08.023_bib60","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/sj.bjp.0703826","article-title":"Rasagiline [N-Propargyl-1R(+)-aminoindant], a selective and potent inhibitor of mitochondrial monoamine oxidase B","volume":"132","author":"Youdim","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.mad.2004.08.023_bib61","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1749-6632.2001.tb03656.x","article-title":"The antiparkinson drug rasagiline and its derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo","volume":"939","author":"Youdim","year":"2001","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.mad.2004.08.023_bib62","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1586\/14737175.3.6.737","article-title":"Rasagiline; an anti-Parkinson drug with neuroprotective activity","volume":"3","author":"Youdim","year":"2003","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.mad.2004.08.023_bib63","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1196\/annals.1306.025","article-title":"Iron out iron in Parkinson's disease and other neurodegenerative diseases with iron chelators; a lesson from 6-hydroxydoapmine and iron chelaros desferal and VK-28","volume":"112","author":"Youdim","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.mad.2004.08.023_bib64","doi-asserted-by":"crossref","unstructured":"Youdim, M.B.H., Fridkin, M., Zheng, H., in press-c. Novel bifucntional drugs targeting monoamine oxidase and iron chelation as a an approach to neuroprotection in Parkinson's disease and other neurodegeneration diseases. J. Neural. Transm. 111, 1455\u20131471.","DOI":"10.1007\/s00702-004-0143-x"},{"key":"10.1016\/j.mad.2004.08.023_bib65","unstructured":"Zheng, H., Weiner, L.M., Bar-Am, O., Cabantchik, I., Warshawsky, A., Fridkin, M., Youdim, M.B.H., in press. Design, synthesis and evaluation of novel iron-chelators as potential agents for treatment of neurodegenerative diseases with iron misregulation. Bio. Org. Chem. (in press)."}],"container-title":["Mechanisms of Ageing and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0047637404002064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0047637404002064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T12:51:54Z","timestamp":1585918314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0047637404002064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["S0047637404002064"],"URL":"https:\/\/doi.org\/10.1016\/j.mad.2004.08.023","relation":{},"ISSN":["0047-6374"],"issn-type":[{"value":"0047-6374","type":"print"}],"subject":[],"published":{"date-parts":[[2005,2]]}}}